Cancer survivor suing NHS after given eight years of chemo instead of six months

He was then prescribed temozolomide chemotherapy and continued on the drug for over eight years – instead of the six months ...
MPR

Ivonescimab Plus Chemotherapy Under Review for EGFR-Mutated NSCLC

Ivonescimab is a first-in-class, investigational bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor.

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemothe…

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug ...

Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug

Investing.com -- Summit Therapeutics Inc. (NASDAQ:SMMT) stock rose 7% Thursday morning after the U.S. Food and Drug ...